Antimicrobial susceptibility and susceptibility testing of Mycoplasma hominis: a review.
The determination of the minimal growth-inhibiting concentration (MIC), the minimal metabolism-inhibiting concentration (MMC), and the minimal mycoplasmacidal concentration (MCC) of various antimicrobial compounds for Mycoplasma hominis is influenced by the pH of the test media, the inoculum size, and the incubation time, although each of these factors generally do not affect the minimal concentration more than fourfold. M. hominis is resistant to beta-lactam antibiotics, vancomycin, sulfonamides, trimethoprim, and polymyxin B. There are great differences in the susceptibility of M. hominis to various macrolide antibiotics. Thus the organism is resistant to erythromycin and oleandomycin, moderately resistant to tylosin and spiramycin, susceptible to josamycin as well as to another macrolide drug, labelled M-4365G. M. hominis is also highly susceptible to the macrolide-like compound rosaramicin and to the tetracyclines (although resistant strains occur). It is susceptible to lincomycin and clindamycin, and moderately susceptible to chloramphenicol and rifampicin. The aminoglycosides have limited activity against M. hominis.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003470:Culture Media; D046508:Culture Techniques; D004352:Drug Resistance, Microbial; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects*; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014295:Trimethoprim / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D003470:Culture Media; D013449:Sulfonamides; D014295:Trimethoprim